Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the Final Deeming Rule; Guidance for Industry; Availability, 22338-22340 [2017-09754]
Download as PDF
22338
Federal Register / Vol. 82, No. 92 / Monday, May 15, 2017 / Notices
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Matters for Discussion: The agenda
will include discussions on:
Meningococcal vaccine; influenza;
hepatitis vaccines; herpes zoster
vaccine; varicella; yellow fever vaccine;
mumps disease and vaccine; Dengue
virus vaccines; Human Papillomavirus
(HPV); Anthrax vaccine workgroup;
Vaccine Adverse Event Reporting
System (VAERS) and vaccine supply. A
recommendation vote is scheduled for
hepatitis vaccines and influenza. A
Vaccines for Children (VFC) vote is
scheduled for hepatitis vaccines.
Agenda items are subject to change as
priorities dictate.
ACIP Charter: https://www.cdc.gov/
vaccines/acip/committee/charter.html.
Contact Person for More Information:
Stephanie Thomas, National Center for
Immunization and Respiratory Diseases,
CDC, 1600 Clifton Road NE., MS–A27,
Atlanta, Georgia 30329, telephone 404/
639–8836; Email ACIP@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–09707 Filed 5–12–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
jstallworth on DSK7TPTVN1PROD with NOTICES
Centers for Disease Control and
Prevention
Interagency Committee on Smoking
and Health: Notice of Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Interagency Committee on Smoking and
Health, Department of Health and
VerDate Sep<11>2014
13:51 May 12, 2017
Jkt 241001
Human Services, has been renewed for
a 2-year period through March 20, 2019.
For information, contact Simon
McNabb, Designated Federal Officer,
Interagency Committee on Smoking and
Health, Centers for Disease Control and
Prevention, Department of Health and
Human Services, Patriot’s Plaza, 395 E
Street SW., M/S P06, Washington, DC
20201, telephone 202/245–0550 or fax
202/245–0599, Email: BOL1@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–09709 Filed 5–12–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–D–2834]
Three-Month Extension of Certain
Tobacco Product Compliance
Deadlines Related to the Final
Deeming Rule; Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
[FR Doc. 2017–09708 Filed 5–12–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcement (FOA)
TS17–001, Identify and Characterize
Potential Environmental Risk Factors for
Amyotrophic Lateral Sclerosis (ALS),
TS17–001.
Summary: This publication corrects a
notice that was published in the Federal
Register on May 4, 2017, Volume 82,
No. 85, page 20895. The meeting time
and date should read as follows:
Time and Date: 8:00 a.m.–6:00 p.m.,
EST, June 14, 2017 (Closed).
Contact Person for More Information:
´
Oscar Tarrago, M.D., M.P.H., Scientific
Review Officer, CDC, 4770 Buford
Highway NE., Mailstop F63, Atlanta,
Georgia 30341, Telephone: (770) 488–
3492.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
PO 00000
Frm 00034
Fmt 4703
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘Three-Month Extension of
Certain Tobacco Product Compliance
Deadlines Related to the Final Deeming
Rule.’’ This guidance is intended to
assist persons who manufacture,
package, sell, offer to sell, distribute, or
import for sale and distribution within
the United States newly regulated
tobacco products, roll-your-own (RYO)
tobacco, and cigarette tobacco in
complying with the Federal Food, Drug,
and Cosmetic Act (the FD&C Act), as
amended by the Family Smoking
Prevention and Tobacco Control Act
(Tobacco Control Act), and FDA
regulations.
SUMMARY:
BILLING CODE 4163–18–P
Sfmt 4703
Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: You may submit comments
as follows:
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
E:\FR\FM\15MYN1.SGM
15MYN1
Federal Register / Vol. 82, No. 92 / Monday, May 15, 2017 / Notices
jstallworth on DSK7TPTVN1PROD with NOTICES
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–D–2834 for ‘‘Three-Month
Extension of Certain Tobacco Product
Compliance Deadlines Announced in
the Final Deeming Rule.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
VerDate Sep<11>2014
13:51 May 12, 2017
Jkt 241001
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for single
copies of this guidance to the Center for
Tobacco Products, Food and Drug
Administration, Document Control
Center, Bldg. 71, Rm. G335, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002. Send one self-addressed
adhesive label to assist that office in
processing your request or include a fax
number to which the guidance
document may be sent. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance.
FOR FURTHER INFORMATION CONTACT:
Deirdre Jurand, Center for Tobacco
Products, Food and Drug
Administration, 10903 New Hampshire
Ave., Document Control Center, Bldg.
71, Rm. G335, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
email: CTPRegulations@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance for industry entitled ‘‘ThreeMonth Extension of Certain Tobacco
Product Compliance Deadlines Related
to the Final Deeming Rule.’’ This
guidance is intended to assist persons
who manufacture, package, sell, offer to
sell, distribute, or import for sale and
distribution within the United States
newly regulated tobacco products, RYO
tobacco, and cigarette tobacco in
complying with the FD&C Act, as
amended by the Tobacco Control Act,
and FDA regulations. We are issuing
this guidance consistent with our good
guidance practices (GGP) regulation
(§ 10.115 (21 CFR 10.115)). We are
implementing this guidance without
prior public comment because we have
determined that prior public
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
22339
participation is not feasible or
appropriate given that the 3-month
extension applies to provisions with
imminent compliance deadlines
(§ 10.115(g)(2)). We made this
determination because FDA needs to
communicate in a timely manner that
the guidance provides a 3-month
extension to the compliance deadlines
for certain provisions under the final
deeming rule that are set for as early as
May 2017. Although this guidance
document is immediately effective, it
remains subject to comment in
accordance with FDA’s GGP regulation.
The Tobacco Control Act (Pub. L.
111–31) granted FDA the authority to
immediately regulate the manufacture,
marketing, and distribution of cigarettes,
cigarette tobacco, RYO, and smokeless
tobacco products to protect the public
health and to reduce tobacco use by
minors.
The Tobacco Control Act also gave
FDA the authority to issue a regulation
deeming all other products that meet the
statutory definition of a tobacco product
to be subject to Chapter IX of the FD&C
Act (section 901(b) (21 U.S.C. 387a(b))
of the FD&C Act). On May 10, 2016,
FDA issued that rule, extending FDA’s
tobacco product authority to all
products that meet the definition of
tobacco product in the law (except for
accessories of newly regulated tobacco
products), including electronic nicotine
delivery systems, cigars, hookah, pipe
tobacco, nicotine gels, dissolvables that
were not already subject to the FD&C
Act, and other tobacco products that
may be developed in the future (81 FR
28974 at 28976) (‘‘the final deeming
rule’’)).1 Chapter IX of the FD&C Act
now applies to newly regulated tobacco
products, including sections 904(a)(1)
and (4) (21 U.S.C.387d(a)(1) and (4))
(ingredient listing, health document
submissions), 903(a)(4) and (a)(8) (21
U.S.C. 387c(a)(4) and (a)(8)) (labeling
requirements), 904(c)(1), 905(b), (c), (d),
(h) (registration), (21 U.S.C. 387e(b), (c),
(d), (h)) 905(i)(1) (product listing),
907(a)(1)(B) (21 U.S.C. 387g(a)(1)(B))
(additional special rule), 911 (21 U.S.C.
387k) (modified risk claims), 904(a)(3)
and 915 (21 U.S.C. 387o) (harmful and
potentially harmful constituent
reporting), and 920 (21 U.S.C. 387t)
(labeling, recordkeeping, records
inspection). The final rule also included
several requirements that apply to a
1 ‘‘Deeming Tobacco Products To Be Subject to
the Federal Food, Drug, and Cosmetic Act, as
Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and
Distribution of Tobacco Products and Required
Warning Statements for Tobacco Products,’’ 81
FR28974 (May 10, 2016).
E:\FR\FM\15MYN1.SGM
15MYN1
22340
Federal Register / Vol. 82, No. 92 / Monday, May 15, 2017 / Notices
subgroup of products referred to as
‘‘covered tobacco products.’’
FDA is providing a 3-month extension
that applies to effective dates and
compliance deadlines for requirements
under the final rule set for May 10,
2017, or later and to all categories of the
newly regulated products, as well as the
addictiveness warning requirement for
RYO and cigarette tobacco.
The guidance represents the current
thinking of the FDA on this topic. It
does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
II. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in section 910(c)(1)(A)(i)
of the FD&C Act and 21 CFR part 1143
have been approved under OMB control
number 0910–0768; the collections of
information in section 905(j) of the
FD&C Act have been approved under
OMB control number 0910–0673; the
collections of information in section
904(a)(4) of the FD&C Act have been
approved under OMB control number
0910–0654; the collections of
information in 21 CFR part 1107 have
been approved under OMB control
number 0910–0684; the collections of
information in section 904(c)(1),
905(b),(c),(d), (h),and 905(i)(1) of the
FD&C Act have been approved under
OMB control number 0910–0650.
III. Electronic Access
jstallworth on DSK7TPTVN1PROD with NOTICES
Persons with access to the Internet
may obtain an electronic version of the
guidance at either https://
www.regulations.gov or https://
www.fda.gov/TobaccoProducts/
Labeling/RulesRegulationsGuidance/
default.htm.
Dated: May 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–09754 Filed 5–12–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
13:51 May 12, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Development of Psychosocial Therapeutic
and Preventive Interventions for Mental
Disorders.
Date: June 2, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel, Early
Stage Testing of Pharmacologic or Devicebased Interventions for the Treatment of
Mental Disorders.
Date: June 7, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
BRAIN Initiative: Research on the Ethical
Implications of Advancements in
Neurotechnology and Brain Science (R01)
RFA.
Date: June 8, 2017.
Time: 12:00 p.m. to 4:00 p.m.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Megan Kinnane, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6148, MSC 9609,
Rockville, MD 20852–9609, 301–402–6807,
libbeym@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281)
Dated: May 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09701 Filed 5–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: HIV/AIDS Innovative Research
Applications.
Date: May 25, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jingsheng Tuo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
Bethesda, MD 20892, 301–451–8754, tuoj@
nei.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
E:\FR\FM\15MYN1.SGM
15MYN1
Agencies
[Federal Register Volume 82, Number 92 (Monday, May 15, 2017)]
[Notices]
[Pages 22338-22340]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09754]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-D-2834]
Three-Month Extension of Certain Tobacco Product Compliance
Deadlines Related to the Final Deeming Rule; Guidance for Industry;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry entitled ``Three-Month
Extension of Certain Tobacco Product Compliance Deadlines Related to
the Final Deeming Rule.'' This guidance is intended to assist persons
who manufacture, package, sell, offer to sell, distribute, or import
for sale and distribution within the United States newly regulated
tobacco products, roll-your-own (RYO) tobacco, and cigarette tobacco in
complying with the Federal Food, Drug, and Cosmetic Act (the FD&C Act),
as amended by the Family Smoking Prevention and Tobacco Control Act
(Tobacco Control Act), and FDA regulations.
DATES: Submit either electronic or written comments on Agency guidances
at any time.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or
[[Page 22339]]
confidential business information, such as a manufacturing process.
Please note that if you include your name, contact information, or
other information that identifies you in the body of your comments,
that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-D-2834 for ``Three-Month Extension of Certain Tobacco Product
Compliance Deadlines Announced in the Final Deeming Rule.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
Submit written requests for single copies of this guidance to the
Center for Tobacco Products, Food and Drug Administration, Document
Control Center, Bldg. 71, Rm. G335, 10903 New Hampshire Ave., Silver
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist
that office in processing your request or include a fax number to which
the guidance document may be sent. See the SUPPLEMENTARY INFORMATION
section for information on electronic access to the guidance.
FOR FURTHER INFORMATION CONTACT: Deirdre Jurand, Center for Tobacco
Products, Food and Drug Administration, 10903 New Hampshire Ave.,
Document Control Center, Bldg. 71, Rm. G335, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, email: CTPRegulations@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a guidance for industry
entitled ``Three-Month Extension of Certain Tobacco Product Compliance
Deadlines Related to the Final Deeming Rule.'' This guidance is
intended to assist persons who manufacture, package, sell, offer to
sell, distribute, or import for sale and distribution within the United
States newly regulated tobacco products, RYO tobacco, and cigarette
tobacco in complying with the FD&C Act, as amended by the Tobacco
Control Act, and FDA regulations. We are issuing this guidance
consistent with our good guidance practices (GGP) regulation (Sec.
10.115 (21 CFR 10.115)). We are implementing this guidance without
prior public comment because we have determined that prior public
participation is not feasible or appropriate given that the 3-month
extension applies to provisions with imminent compliance deadlines
(Sec. 10.115(g)(2)). We made this determination because FDA needs to
communicate in a timely manner that the guidance provides a 3-month
extension to the compliance deadlines for certain provisions under the
final deeming rule that are set for as early as May 2017. Although this
guidance document is immediately effective, it remains subject to
comment in accordance with FDA's GGP regulation.
The Tobacco Control Act (Pub. L. 111-31) granted FDA the authority
to immediately regulate the manufacture, marketing, and distribution of
cigarettes, cigarette tobacco, RYO, and smokeless tobacco products to
protect the public health and to reduce tobacco use by minors.
The Tobacco Control Act also gave FDA the authority to issue a
regulation deeming all other products that meet the statutory
definition of a tobacco product to be subject to Chapter IX of the FD&C
Act (section 901(b) (21 U.S.C. 387a(b)) of the FD&C Act). On May 10,
2016, FDA issued that rule, extending FDA's tobacco product authority
to all products that meet the definition of tobacco product in the law
(except for accessories of newly regulated tobacco products), including
electronic nicotine delivery systems, cigars, hookah, pipe tobacco,
nicotine gels, dissolvables that were not already subject to the FD&C
Act, and other tobacco products that may be developed in the future (81
FR 28974 at 28976) (``the final deeming rule'')).\1\ Chapter IX of the
FD&C Act now applies to newly regulated tobacco products, including
sections 904(a)(1) and (4) (21 U.S.C.387d(a)(1) and (4)) (ingredient
listing, health document submissions), 903(a)(4) and (a)(8) (21 U.S.C.
387c(a)(4) and (a)(8)) (labeling requirements), 904(c)(1), 905(b), (c),
(d), (h) (registration), (21 U.S.C. 387e(b), (c), (d), (h)) 905(i)(1)
(product listing), 907(a)(1)(B) (21 U.S.C. 387g(a)(1)(B)) (additional
special rule), 911 (21 U.S.C. 387k) (modified risk claims), 904(a)(3)
and 915 (21 U.S.C. 387o) (harmful and potentially harmful constituent
reporting), and 920 (21 U.S.C. 387t) (labeling, recordkeeping, records
inspection). The final rule also included several requirements that
apply to a
[[Page 22340]]
subgroup of products referred to as ``covered tobacco products.''
---------------------------------------------------------------------------
\1\ ``Deeming Tobacco Products To Be Subject to the Federal
Food, Drug, and Cosmetic Act, as Amended by the Family Smoking
Prevention and Tobacco Control Act; Restrictions on the Sale and
Distribution of Tobacco Products and Required Warning Statements for
Tobacco Products,'' 81 FR28974 (May 10, 2016).
---------------------------------------------------------------------------
FDA is providing a 3-month extension that applies to effective
dates and compliance deadlines for requirements under the final rule
set for May 10, 2017, or later and to all categories of the newly
regulated products, as well as the addictiveness warning requirement
for RYO and cigarette tobacco.
The guidance represents the current thinking of the FDA on this
topic. It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information. These collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501-3520). The collections of information in
section 910(c)(1)(A)(i) of the FD&C Act and 21 CFR part 1143 have been
approved under OMB control number 0910-0768; the collections of
information in section 905(j) of the FD&C Act have been approved under
OMB control number 0910-0673; the collections of information in section
904(a)(4) of the FD&C Act have been approved under OMB control number
0910-0654; the collections of information in 21 CFR part 1107 have been
approved under OMB control number 0910-0684; the collections of
information in section 904(c)(1), 905(b),(c),(d), (h),and 905(i)(1) of
the FD&C Act have been approved under OMB control number 0910-0650.
III. Electronic Access
Persons with access to the Internet may obtain an electronic
version of the guidance at either https://www.regulations.gov or
https://www.fda.gov/TobaccoProducts/Labeling/RulesRegulationsGuidance/default.htm.
Dated: May 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-09754 Filed 5-12-17; 8:45 am]
BILLING CODE 4164-01-P